About US
Contact us
-
J&J, in rebuttal to pricing criticism, says antidepressant Spravato is cost-effectiveDays ago, Johnson & Johnson’s controversial nasal depression drug Spravato was criticized as being too pricey. In response, the company has now come up with its own study to champion the drug’s c2019/5/23
-
Merck's powerhouse Keytruda whiffs breast cancer trial, delaying hopes for new useRight now, Roche’s Tecentriq is the only immuno-oncology drug approved in triple negative breast cancer. And it looks like it’ll stay that way for awhile. Merck's steamroller Keytruda turned in a rar2019/5/22
-
Hurting for revenue, Mylan shells out $130M for basket of Aspen drugsWith share prices tumbling and a massive drug-price fixing lawsuit hanging over its head, Mylan’s future is looking increasingly spooky. Could a modest acquisition help turn the tide? It's willing to2019/5/22
-
Lawmakers clash as Gilead CEO takes congressional hot seat to defend TruvadaGilead Sciences' important HIV business has been under fire in recent weeks, with lawsuits and critics airing allegations about the company’s pricing, patents and more. On Thursday, the company’s n2019/5/21
-
After Oklahoma payout, Purdue faces 5 new state lawsuits over OxyContinPurdue Pharma and its founding family took a quarter-of-a-billion-dollar hit when it settled with the state of Oklahoma over a lawsuit accusing the company of pushing false and misleading ads for pow2019/5/21
-
AstraZeneca's Fasenra offers severe asthma patients 2 years of benefits: analysisAstraZeneca’s Fasenra has been stealing share from GlaxoSmithKline’s Nucala in severe asthma, and competition is even fiercer with Sanofi’s Dupixent approval. Now, AZ has released an analysis of se2019/5/20
-
NICE grants Celgene long-awaited thumbs-up for Revlimid in untreated myelomaThe old adage “better late than never” may be overused, but forCelgene, it certainly applies to England’s cost watchdogs and their stance toward the company's multiple myeloma flagship drug Revlimid.2019/5/20
-
Celgene’s Pomalyst secures breakthrough designationThe US Food and Drug Administration (FDA) has awarded breakthrough therapy designation to Celgene’s Pomalyst (pomalidomide) in HIV-positive and HIV-negative Kaposi sarcoma. Pomalyst is an oral, small2019/5/17
-
Biogen’s SMA drug Spinraza to be available on NHSThe UK’s National Health Service (NHS) has signed a managed access agreement to fund Biogen’s antisense oligonucleotide (ASO) Spinraza (nusinersen) for a limited time to ascertain its effectiveness a2019/5/17
-
Gilead tries—and fails—to dodge lawsuit claiming it delayed safer HIV medsGilead Sciences has faced years of allegations that it sidelinedits safer, next-gen HIV drugs to reap as much revenue as possible from the older generation before the new meds hit.And a federal jud2019/5/16